Zoonotic and emerging infectious diseases represent an increasing and very real threat to global health, and it is essential that we expand our understanding of the pathogenesis and prevention of these diseases because of the increasing density of human populations, the increased exposure to domestic animal populations, and the crowding of wildlife into limited areas with frequent human contact. To address the need for infectious disease research capabilities, a COBRE Center of Excellence was established at Montana State University (MSU), with the goal of positioning Montana as a national leader in research on the pathogenesis of zoonotic infectious diseases. Over the past four years, the Center has been extremely successful, resulting in development of infrastructure, recruitment and support of junior investigators, and formation of a cohesive Center of investigators. The synergism of these components has resulted in the establishment of a solid foundation for expansion of infectious disease research in the region. With this infrastructure in place, we are now ideally poised to expand and strengthen the Center as a scalable and sustainable research enterprise. Our long term goal is to establish a sustainable Center of Excellence that is focused on understanding pathogenesis, host immune responses, and therapeutic development for zoonotic and emerging infectious diseases of regional and worldwide importance. While the foundation for this goal has been established through accomplishments realized during COBRE I, there is still a critical need for further faculty development, infrastructure enhancement, and recruitment of additional researchers in the area of zoonotic and emerging infectious diseases, and three specific aims are proposed to address these needs. First, we propose a pipeline to foster the development of current junior investigators so that funding and infrastructure resources are available at critical junctures in their careers. Secondly, we propose to increase the size, scope, and competitiveness of the Center through four new faculty hires. Together, accomplishment of these two aims will lead to establishment of the critical mass of investigators needed to sustain the Center and support future infectious disease research initiatives. Finally, we propose to strengthen the infectious disease research infrastructure in Montana through support and enhancement of established COBRE core facilities. Because of the success of COBRE I, the proven scientific abilities of the Center investigators, the outstanding institutional support, and the emphasis on a timely and increasingly important area of research, we believe that COBRE II support will lead to completion of a scalable and sustainable Center of Excellence in zoonotic and emerging infectious disease research.

Public Health Relevance

Many of the important and emerging Infectious diseases of humans are zoonotic, and most are also potential weapons of bioterrorism. Furthermore, a number of these diseases have reservoirs in the livestock and wildlife of our nation. COBRE II will strengthen and enrich our Center of Excellence in infectious disease research, providing the resources needed to advance our understanding of disease pathogenesis and facilitating development of novel therapeutic treatments.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Exploratory Grants (P20)
Project #
8P20GM103500-09
Application #
8306748
Study Section
Special Emphasis Panel (ZRR1-RI-B (01))
Program Officer
Gorospe, Rafael
Project Start
2004-09-29
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
9
Fiscal Year
2012
Total Cost
$2,125,559
Indirect Cost
$633,939
Name
Montana State University - Bozeman
Department
Veterinary Sciences
Type
Schools of Earth Sciences/Natur
DUNS #
625447982
City
Bozeman
State
MT
Country
United States
Zip Code
59717
Schepetkin, Igor A; Kirpotina, Liliya N; Mitchell, Pete T et al. (2018) The natural sesquiterpene lactones arglabin, grosheimin, agracin, parthenolide, and estafiatin inhibit T cell receptor (TCR) activation. Phytochemistry 146:36-46
Borges, Adair L; Zhang, Jenny Y; Rollins, MaryClare F et al. (2018) Bacteriophage Cooperation Suppresses CRISPR-Cas3 and Cas9 Immunity. Cell 174:917-925.e10
van Erp, Paul B G; Patterson, Angela; Kant, Ravi et al. (2018) Conformational Dynamics of DNA Binding and Cas3 Recruitment by the CRISPR RNA-Guided Cascade Complex. ACS Chem Biol 13:481-490
Chowdhury, Saikat; Carter, Joshua; Rollins, MaryClare F et al. (2017) Structure Reveals Mechanisms of Viral Suppressors that Intercept a CRISPR RNA-Guided Surveillance Complex. Cell 169:47-57.e11
Stama, Madia Letizia; ?lusarczyk, Joanna; Lacivita, Enza et al. (2017) Novel ureidopropanamide based N-formyl peptide receptor 2 (FPR2) agonists with potential application for central nervous system disorders characterized by neuroinflammation. Eur J Med Chem 141:703-720
Jackson, Ryan N; van Erp, Paul Bg; Sternberg, Samuel H et al. (2017) Conformational regulation of CRISPR-associated nucleases. Curr Opin Microbiol 37:110-119
Luo, Michelle L; Jackson, Ryan N; Denny, Steven R et al. (2016) The CRISPR RNA-guided surveillance complex in Escherichia coli accommodates extended RNA spacers. Nucleic Acids Res 44:7385-94
Criddle, A; Thornburg, T; Kochetkova, I et al. (2016) gD-Independent Superinfection Exclusion of Alphaherpesviruses. J Virol 90:4049-58
Qazi, Shefah; Miettinen, Heini M; Wilkinson, Royce A et al. (2016) Programmed Self-Assembly of an Active P22-Cas9 Nanocarrier System. Mol Pharm 13:1191-6
van Erp, Paul Bg; Bloomer, Gary; Wilkinson, Royce et al. (2015) The history and market impact of CRISPR RNA-guided nucleases. Curr Opin Virol 12:85-90

Showing the most recent 10 out of 75 publications